Highlights

  • Q3 2025 organic revenue grew by over 3.4% with price up 1.8% and volume/mix up 1.6%.
  • Haleon reported total revenue of GBP 2,799 million.
  • Organic revenue growth expected around 3.5% in FY25 along with high single-digit operating profit growth.

Haleon plc (LSE:HLN) has reported a 3.4% increase in organic revenue for the third quarter of 2025, supported by performance in its Oral Health and Vitamins, Minerals and Supplements (VMS) categories. The company reaffirmed its full-year guidance for 2025, citing continued innovation and disciplined capital allocation as key drivers of growth.

Third Quarter Overview

For the three months ended 30 September 2025, Haleon reported total revenue of GBP 2,799 million, representing 0.7% reported growth and 3.4% organic growth. The company attributed the increase to product innovation, steady consumer demand, and continued recovery across key markets.

Growth in price contributed 1.8 percentage points, while volume and mix added 1.6 percentage points, reflecting stable consumption trends across major product categories.

Performance by Geography

The company’s EMEA & Latin America segment delivered 5.3% organic growth, while the Asia-Pacific region grew 5.1%, supported by demand in China and India. Emerging markets revenue rose 7.1%, with India recording double-digit growth and China growing at a mid-single-digit rate.

In North America, organic growth was modest at 0.4%, with consumption growth outperforming the overall market despite a reported revenue decline of 2.0%.

Category Performance

Haleon’s Oral Health segment remained a standout performer, achieving 6.9% organic revenue growth to GBP 867 million, driven by the ongoing rollout of Sensodyne’s Clinical Platform and new product introductions under parodontax and Polident/Poligrip.

The VMS category reported 4.9% organic growth, supported by the Centrum brand, particularly in EMEA and Latin America. Pain Relief products, including Panadol Dual Action and Voltaren 2%, grew 3.7%, while Respiratory Health declined 1.8% organically due to a mild cold and flu season and prior-year comparatives.

Digestive Health rose 2.1%, whereas Therapeutic Skin Health and Other fell 1.1%.

Innovation and Product Development

The quarter saw several new product launches, including Otrivin Nasal Mist, Panadol Dual Action, and further innovations within the Centrum Daily Kits line in China. Haleon stated that ongoing investment in product innovation remains central to sustaining its growth trajectory across key global markets.

Capital Allocation and Shareholder Returns

During the first nine months of 2025, Haleon returned approximately GBP 1.1 billion to shareholders—comprising GBP 500 million in share buybacks and GBP 600 million in dividends—as part of its capital allocation framework focused on long-term value creation.

Full-Year 2025 Outlook

Haleon reaffirmed its FY 2025 guidance, expecting:

  • Organic revenue growth of around 3.5%, assuming a normal cold and flu season.
  • High single-digit organic operating profit growth driven by positive operating leverage.
  • A net interest charge of approximately GBP 260 million and an adjusted effective tax rate of around 24.5%.

The company also noted that the net impact of mergers and acquisitions, including the disposals of ChapStick and its non-US Nicotine Replacement Therapy business in 2024, is expected to dilute FY 2025 revenue by about 2% and adjusted operating profit by approximately 5.5%.

HLN shares were trading at GBX 350.20 per share at the time of writing on 30 October 2025.